Skip to main content

Biogen diluted shares

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Biogen's diluted shares was 147M shares for fiscal year 2025 (the twelve months to 31 Dec 2025), up 0.8% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was 148M shares, up 0.5% from a year earlier.

From Biogen's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 28 Oct 2026.

Fiscal 2025
147M
+0.8%
Q3 FY2026
148M
+0.5% on a year
Growth over 9 years
−4.3%
a year, FY 2016–FY 2025

Diluted shares by fiscal year

219MFY 2016213MFY 2017−2.7%205MFY 2018−3.6%187MFY 2019−8.7%161MFY 2020−13.9%150MFY 2021−7.3%146MFY 2022−2.4%146MFY 2023−0.3%146MFY 2024+0.2%147MFY 2025+0.8%

Change on the year before, under each year. From FY 2016 to FY 2025, Biogen's diluted shares went from 219M shares to 147M shares, a compound annual change of −4.3%; the highest was 219M shares in FY 2016.

Biogen diluted shares, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Diluted shares219M213M205M187M161M150M146M146M146M147M
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Diluted shares by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Biogen diluted shares, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Diluted shares145M147M147M147M148M148M149M148M
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How diluted shares is measured

Diluted shares is the weighted average number of shares outstanding in the period, counting the shares that options, warrants and convertible securities could add; it is the count earnings per share is divided by. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Biogen's other figures

Diluted shares of comparable companies

Everything on BIIB, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.